Anika Therapeutics (ANIK) Set to Post Earnings on Friday

Anika Therapeutics (NASDAQ:ANIK) is expected to be announcing its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect Anika Therapeutics to announce earnings of $0.42 per share and revenue of $29.44 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 6, 2026 at 8:30 AM ET.

Anika Therapeutics Trading Up 4.9%

Shares of ANIK opened at $20.40 on Thursday. Anika Therapeutics has a 12 month low of $9.01 and a 12 month high of $22.88. The firm’s 50 day moving average is $20.56 and its 200-day moving average is $16.18. The stock has a market capitalization of $272.95 million, a PE ratio of 972.50, a P/E/G ratio of 13.89 and a beta of 0.21.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on ANIK shares. B. Riley Financial initiated coverage on Anika Therapeutics in a research report on Friday, September 18th. They issued a “buy” rating and a $23.00 price target on the stock. Barrington Research set a $21.00 target price on Anika Therapeutics in a report on Thursday, July 30th. Zacks Research lowered Anika Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Anika Therapeutics in a research report on Monday, September 21st. Finally, Wall Street Zen upgraded Anika Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 1st. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $22.00.

About Anika Therapeutics

Anika Therapeutics, Inc develops, manufactures and commercializes therapeutic products designed to support tissue protection, healing and repair. The company focuses primarily on orthopedics, with products based in part on hyaluronic acid, a naturally occurring substance found in connective tissue and joint fluid.

Anika’s orthopedic portfolio includes Monovisc and Orthovisc, viscosupplementation products used to help relieve pain associated with osteoarthritis of the knee, as well as Cingal, which combines hyaluronic acid with a corticosteroid.